Forman HJ1, Zhang H, Rinna A
Oral semaglutide (the Wegovy pill) Novo Nordisk launched an oral form of semaglutide for weight loss in the US in January 2026
A 2025 meta-analysis pooling three trials (878 participants) confirmed the pattern: significantly greater weight loss than placebo about ~14% of total body weight on average with no significant rise in overall adverse events [6] [7]
Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V
Ultraviolet-visible spectroscopy of the d-d absorption band is a cheap, non-destructive complement that reports on coordination rather than on total metal, and the two together are far more informative than either alone
Healthcare providers considering this combination should implement enhanced monitoring protocols and maintain heightened vigilance for adverse effects